Michele Ghidini, MD, PhD, medical oncologist, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, discusses the effects of body weight loss in gastric/gastroesophageal junction (GEJ) cancer. 

The phase 3 TAGS trial demonstrated clinical benefit with trifluridine/tipiracil (TAS-102; Lonsurf) vs placebo in patients with metastatic gastric/GEJ cancer who had received 2 or more prior chemotherapy regimens. During the 2021 Gastrointestinal Cancers Symposium, findings from a post-hoc analysis of the TAGS trial showed that early body weight loss of 3% or greater was a strong negative prognostic factor for overall survival (OS) irrespective of treatment with TAS-102 or placebo.

In the TAS-102 arm, the median OS was 6.5 months in patients who had less than 3% body weight loss and 4.9 months in those who had 3% or more body weight loss. In the placebo arm, the median OS was 6.0 months vs 2.5 months, respectively. Median progression-free survival was also improved in patients who had less than 3% body weight loss. Similar findings were observed in a univariate and multivariate analysis. 

As such, the data suggest that body weight loss is a good prognostic and predictive factor for OS in patients with previously treated, metastatic gastric/GEJ cancer who were treated on the TAGS trial and had available body weight loss data, concludes Ghidini.

Videos

Michele Ghidini, MD, PhD, discusses the effects of body weight loss in gastric/gastroesophageal junction cancer.  

Michele Ghidini, MD, PhD

Articles

Dr. Ghidini on the Effects of Body Weight Loss in Gastric/GEJ Cancer